Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

The receptor protein tyrosine phosphatase PTPRB negatively regulates FGF2-dependent branching morphogenesis.

Soady KJ, Tornillo G, Kendrick H, Meniel V, Olijnyk-Dallis D, Morris JS, Stein T, Gusterson BA, Isacke CM, Smalley MJ.

Development. 2017 Oct 15;144(20):3777-3788. doi: 10.1242/dev.149120. Epub 2017 Sep 4.

2.

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.

Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thürlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M; International Breast Cancer Study Group and the BIG 1-98 Collaborative Group.

Ann Oncol. 2015 Dec;26(12):2442-9. doi: 10.1093/annonc/mdv391. Epub 2015 Sep 19.

3.

RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland.

McDonald L, Ferrari N, Terry A, Bell M, Mohammed ZM, Orange C, Jenkins A, Muller WJ, Gusterson BA, Neil JC, Edwards J, Morris JS, Cameron ER, Blyth K.

Dis Model Mech. 2014 May;7(5):525-34. doi: 10.1242/dmm.015040. Epub 2014 Mar 13.

4.

Fibulin-2 is involved in early extracellular matrix development of the outgrowing mouse mammary epithelium.

Olijnyk D, Ibrahim AM, Ferrier RK, Tsuda T, Chu ML, Gusterson BA, Stein T, Morris JS.

Cell Mol Life Sci. 2014 Oct;71(19):3811-28. doi: 10.1007/s00018-014-1577-4. Epub 2014 Feb 13.

PMID:
24522256
5.

Human breast development.

Gusterson BA, Stein T.

Semin Cell Dev Biol. 2012 Jul;23(5):567-73. doi: 10.1016/j.semcdb.2012.03.013. Epub 2012 Mar 16. Review.

PMID:
22426022
6.

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Ann Oncol. 2011 Oct;22(10):2201-7. doi: 10.1093/annonc/mdq738. Epub 2011 Feb 18.

7.

Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Collins J, Murray E, Zaman K, Colleoni M, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A.

Ann Oncol. 2011 Oct;22(10):2216-26. doi: 10.1093/annonc/mdq735. Epub 2011 Feb 16.

8.

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.

Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simoncini E, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A.

Ann Oncol. 2011 Sep;22(9):1981-7. doi: 10.1093/annonc/mdq754. Epub 2011 Jan 31.

9.

Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis.

Stein T, Cosimo E, Yu X, Smith PR, Simon R, Cottrell L, Pringle MA, Bell AK, Lattanzio L, Sauter G, Lo Nigro C, Crook T, Machesky LM, Gusterson BA.

Am J Pathol. 2010 Nov;177(5):2323-33. doi: 10.2353/ajpath.2010.100209. Epub 2010 Sep 16.

10.

A prophylactic vaccine for breast cancer?

Watson CJ, Gusterson BA.

Breast Cancer Res. 2010;12(4):310. doi: 10.1186/bcr2628. Epub 2010 Aug 31.

11.

Poor early growth and excessive adult calorie intake independently and additively affect mitogenic signaling and increase mammary tumor susceptibility.

Fernandez-Twinn DS, Ekizoglou S, Martin-Gronert MS, Tarry-Adkins J, Wayman AP, Warner MJ, Luan JA, Gusterson BA, Ozanne SE.

Carcinogenesis. 2010 Oct;31(10):1873-81. doi: 10.1093/carcin/bgq095. Epub 2010 May 11.

PMID:
20460357
12.

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, Coates AS, Gusterson BA.

J Clin Oncol. 2010 Jun 20;28(18):2966-73. doi: 10.1200/JCO.2009.25.9549. Epub 2010 May 10.

13.

TSC-22D1 isoforms have opposing roles in mammary epithelial cell survival.

Huser CA, Pringle MA, Heath VJ, Bell AK, Kendrick H, Smalley MJ, Crighton D, Ryan KM, Gusterson BA, Stein T.

Cell Death Differ. 2010 Feb;17(2):304-15. doi: 10.1038/cdd.2009.126. Epub 2009 Sep 11.

14.

Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.

Viale G, Giobbie-Hurder A, Gusterson BA, Maiorano E, Mastropasqua MG, Sonzogni A, Mallon E, Colleoni M, Castiglione-Gertsch M, Regan MM, Price KN, Brown RW, Golouh R, Crivellari D, Karlsson P, Ohlschlegel C, Gelber RD, Goldhirsch A, Coates AS.

Ann Oncol. 2010 Feb;21(2):245-54. doi: 10.1093/annonc/mdp317. Epub 2009 Jul 24.

15.

Should we be surprised at the paucity of response to EGFR inhibitors?

Gusterson BA, Hunter KD.

Lancet Oncol. 2009 May;10(5):522-7. doi: 10.1016/S1470-2045(09)70034-8. Review.

PMID:
19410197
16.

A mouse mammary gland involution mRNA signature identifies biological pathways potentially associated with breast cancer metastasis.

Stein T, Salomonis N, Nuyten DS, van de Vijver MJ, Gusterson BA.

J Mammary Gland Biol Neoplasia. 2009 Jun;14(2):99-116. doi: 10.1007/s10911-009-9120-1. Epub 2009 Apr 30. Review. Erratum in: J Mammary Gland Biol Neoplasia. 2009 Jun;14(2):117-9.

PMID:
19408105
17.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98.

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.

18.

Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.

Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group.

J Clin Oncol. 2008 Jun 20;26(18):3006-14. doi: 10.1200/JCO.2007.14.9336. Epub 2008 May 5.

PMID:
18458044
19.

Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.

Gruber G, Cole BF, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Price KN, Goldhirsch A, Viale G, Gusterson BA; International Breast Cancer Study Group.

Ann Oncol. 2008 Aug;19(8):1393-401. doi: 10.1093/annonc/mdn123. Epub 2008 Apr 2.

20.

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.

J Clin Oncol. 2008 Mar 20;26(9):1404-10. doi: 10.1200/JCO.2007.10.6393.

PMID:
18349391
21.

p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.

Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G; International Breast Cancer Study Group.

Ann Oncol. 2008 Apr;19(4):660-8. doi: 10.1093/annonc/mdm547. Epub 2008 Feb 13.

22.

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS; International Breast Cancer Study Group.

J Natl Cancer Inst. 2008 Feb 6;100(3):207-12. doi: 10.1093/jnci/djm289. Epub 2008 Jan 29.

PMID:
18230798
23.

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Lancet Oncol. 2008 Jan;9(1):23-8. Epub 2007 Dec 20.

PMID:
18083065
24.

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.

J Clin Oncol. 2007 Sep 1;25(25):3846-52. Epub 2007 Aug 6.

PMID:
17679725
25.

Mammary gland involution as a multi-step process.

Stein T, Salomonis N, Gusterson BA.

J Mammary Gland Biol Neoplasia. 2007 Mar;12(1):25-35. Review.

PMID:
17431797
26.

The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.

Karlsson P, Cole BF, Price KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, Murray E, Lindtner J, Collins JP, Holmberg SB, Fey MF, Thürlimann B, Crivellari D, Forbes JF, Gelber RD, Goldhirsch A, Wallgren A.

J Clin Oncol. 2007 May 20;25(15):2019-26. Epub 2007 Apr 9.

PMID:
17420511
27.

Proteomic analysis of the mouse mammary gland is a powerful tool to identify novel proteins that are differentially expressed during mammary development.

Davies CR, Morris JS, Griffiths MR, Page MJ, Pitt A, Stein T, Gusterson BA.

Proteomics. 2006 Nov;6(21):5694-704.

PMID:
17022101
28.

Compensatory mammary growth following protein restriction during pregnancy and lactation increases early-onset mammary tumor incidence in rats.

Fernandez-Twinn DS, Ekizoglou S, Gusterson BA, Luan J, Ozanne SE.

Carcinogenesis. 2007 Mar;28(3):545-52. Epub 2006 Sep 4.

PMID:
16952910
29.

Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer.

Stein T, Price KN, Morris JS, Heath VJ, Ferrier RK, Bell AK, Pringle MA, Villadsen R, Petersen OW, Sauter G, Bryson G, Mallon EA, Gusterson BA.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6872-9.

30.

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.

Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF; Breast Cancer Linkage Consortium.

Clin Cancer Res. 2005 Jul 15;11(14):5175-80.

31.

Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer.

Gusterson BA, Ross DT, Heath VJ, Stein T.

Breast Cancer Res. 2005;7(4):143-8. Epub 2005 May 5. Review.

32.

Involvement of axonal guidance proteins and their signaling partners in the developing mouse mammary gland.

Morris JS, Stein T, Pringle MA, Davies CR, Weber-Hall S, Ferrier RK, Bell AK, Heath VJ, Gusterson BA.

J Cell Physiol. 2006 Jan;206(1):16-24.

PMID:
15920758
33.

Proteomic analysis of mouse mammary terminal end buds identifies axonal growth cone proteins.

Morris JS, Davies CR, Griffiths MR, Page MJ, Bruce JA, Patel T, Herath A, Gusterson BA.

Proteomics. 2004 Jun;4(6):1802-10.

PMID:
15174146
34.

Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3.

Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ, Bell AK, Ferrier RK, Sandilands GP, Gusterson BA.

Breast Cancer Res. 2004;6(2):R75-91. Epub 2003 Dec 18.

35.

The new TNM classification and micrometastases.

Gusterson BA.

Breast. 2003 Dec;12(6):387-90.

36.

Is research on human tissues at a crossroads?

Hair JF, McNicol AM, Gusterson BA.

Eur J Cancer. 2003 Nov;39(16):2253-5. No abstract available.

PMID:
14556914
37.

Development of novel selective cell ablation in the mammary gland and brain to study cell-cell interactions and chemoprevention.

Gusterson BA, Cui W, Clark AJ.

Recent Results Cancer Res. 2003;163:31-45; discussion 264-6. Review.

PMID:
12903841
38.

Distinct genetic and epigenetic changes in medullary breast cancer.

Osin P, Lu YJ, Stone J, Crook T, Houlston RS, Gasco M, Gusterson BA, Shipley J.

Int J Surg Pathol. 2003 Jul;11(3):153-8.

PMID:
12894346
39.

Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.

Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A; International Breast Cancer Study Group.

Cancer. 2003 Apr 1;97(7):1591-600.

40.

Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?

Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA; International Breast Cancer Study Group.

Cancer. 2003 Mar 1;97(5):1321-31.

41.

LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.

Baltayan A, Naritoku WY, Chaiwun B, Tsao-Wei DD, Groshen S, Hern RA, Gusterson BA, Taylor CR, Imam SA.

Anticancer Res. 2002 Sep-Oct;22(5):2933-7.

PMID:
12530020
42.

Mutations of the BRAF gene in human cancer.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA.

Nature. 2002 Jun 27;417(6892):949-54. Epub 2002 Jun 9.

PMID:
12068308
43.

What the clinician needs from the pathologist: evidence-based reporting in breast cancer.

Going JJ, Mallon EA, Leake RE, Bartlett JM, Gusterson BA.

Eur J Cancer. 2001 Oct;37 Suppl 7:S5-17. Review.

PMID:
11888005
44.

Inhibition of myc-dependent breast tumor formation in transgenic mice.

Cui W, Gusterson BA, Clark AJ.

Breast Cancer Res Treat. 2002 Jan;71(1):9-20.

PMID:
11859878
45.

Concomitant inactivation of p53 and Chk2 in breast cancer.

Sullivan A, Yuille M, Repellin C, Reddy A, Reelfs O, Bell A, Dunne B, Gusterson BA, Osin P, Farrell PJ, Yulug I, Evans A, Ozcelik T, Gasco M, Crook T.

Oncogene. 2002 Feb 21;21(9):1316-24.

46.

Human breast development.

Howard BA, Gusterson BA.

J Mammary Gland Biol Neoplasia. 2000 Apr;5(2):119-37. Review.

PMID:
11149569
47.

Retroviral expression of Wnt-1 and Wnt-7b produces different effects in mouse mammary epithelium.

Naylor S, Smalley MJ, Robertson D, Gusterson BA, Edwards PA, Dale TC.

J Cell Sci. 2000 Jun;113 ( Pt 12):2129-38.

48.

The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.

Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Futreal PA, Peto J, Stoppa-Lyonnet D, Bignon YJ, Stratton MR.

Clin Cancer Res. 2000 Mar;6(3):782-9.

49.

The characterization of a mouse mutant that displays abnormal mammary gland development.

Howard BA, Gusterson BA.

Mamm Genome. 2000 Mar;11(3):234-7. No abstract available.

PMID:
10723730
50.

The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting.

Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE.

Oncogene. 2000 Feb 21;19(8):968-88. Review.

PMID:
10713680

Supplemental Content

Loading ...
Support Center